SCHEDULE 13G/A: Point72 Reduces Stake in Cogent Biosciences to 4.0%

Point72 Asset Management and its affiliates reported a reduced beneficial ownership stake of 4.0% in Cogent Biosciences, Inc., including convertible preferred stock.

Summary

• Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported beneficial ownership of 5,753,833 shares of Cogent Biosciences, Inc. common stock.
• This represents a 4.0% stake in the company's common stock, calculated based on 144,216,796 shares outstanding as of September 30, 2025.
• The reported ownership includes 4,516,000 shares of common stock issuable upon conversion of Series B Non-Voting Preferred Stock.
• The reporting persons hold shared voting power and shared dispositive power over all 5,753,833 shares.
• This filing is an Amendment No. 4 to a previous Schedule 13G, indicating a change in their holding.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in beneficial ownership by a prominent institutional investor, Point72 Asset Management, to below the 5% threshold, which is generally viewed as a negative development for the company's stock.

Negatives

• Point72 Asset Management and its affiliates have reduced their beneficial ownership in Cogent Biosciences, Inc. to 4.0%, falling below the 5% threshold typically associated with significant institutional holdings.

Risks

• The decrease in beneficial ownership by Point72 Asset Management to 4.0% may be interpreted by the market as a reduced conviction in Cogent Biosciences, Inc. by a significant institutional investor.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The reduction in Point72's stake could lead to negative market sentiment and potentially downward pressure on the stock price.
• Company Management: May need to address investor concerns or provide clarity on the company's strategy to retain institutional confidence.

Key Dates

Recommendation

The filing indicates that Point72 Asset Management, a prominent institutional investor, has reduced its beneficial ownership in Cogent Biosciences, Inc. to 4.0%, which is below the 5% threshold. This reduction by a sophisticated investor suggests a potential loss of conviction or a strategic reallocation of capital away from Cogent Biosciences, Inc. Such a move by a significant holder is typically interpreted as a negative signal by the market and could lead to downward pressure on the stock price. Therefore, a seasoned investor might consider selling their position.

Keywords

Cogent Biosciences, Point72 Asset Management, Steven A. Cohen, Schedule 13G, beneficial ownership, common stock, preferred stock, institutional investment, SEC filing, equity stake